Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Co...
July 19 2021 - 4:01PM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four
posters at the International Society for Thrombosis and Haemostasis
(ISTH) 2021 Virtual Congress, being held July 17-21, 2021.
The first poster, entitled: “Subcutaneous Marzeptacog Alfa
(Activated) Effectively Treats Bleeding in FVII Deficient Rats Both
When Administered Prior To or After Bleeding Has Started,” was
presented by Tom Knudsen, DVM, Ph.D., senior vice president,
corporate development, Catalyst Biosciences, who also presented the
second and third posters. The study was conducted using an animal
model to investigate the effect of subcutaneous (SQ) marzeptacog
alfa (MarzAA) on tail vein transection (TVT) bleeding in FVII
deficient rats. The data demonstrated that SQ MarzAA corrects the
bleeding phenotype in FVII deficient rats when administered prior
to or even after bleeding has started in a TVT bleeding model.
The second poster, entitled: “Dose Selection for Subcutaneous
Marzeptacog Alfa (Activated) in Subjects with Factor VII Deficiency
Using Population Pharmacometric Clinical Trial Simulations,”
highlighted work done in support of the dose selection for SQ
MarzAA in planned clinical trials. The objective of the study was
to conduct simulations using a MarzAA-specific, population
pharmacokinetic (PK) model in a large population following
different dose levels of MarzAA. The simulations indicated that
hemostasis may be achieved with the proposed trial doses and
sufficient exposure levels may be sustained in two-thirds or more
of subjects for 24 hours even after a single SQ MarzAA dose of 20
µg/kg, and almost all subjects at higher doses.
The third poster, entitled: “Dose Selection of Marzeptacog Alfa
(Activated) in Children with Hemophilia: A Population
Pharmacokinetic Exposure Matching Strategy,” presented data using
clinical trial simulation to support pediatric trial dose selection
for SQ MarzAA in children with Hemophilia A or B with inhibitors.
The population pharmacokinetics simulation supported selecting a 60
µg/kg SQ dose of MarzAA in a pediatric clinical trial, similar to
the dose in the ongoing clinical trial in adult and adolescent
subjects.
The fourth poster, entitled: “Mitigation of Injection Site
Reactions After Subcutaneous Administration of Dalcinonacog Alfa
(DalcA) in Hemophilia B Using Preclinical Models,” was presented by
Natacha Le Moan, Ph.D., senior director, translational research,
Catalyst Biosciences. The study was conducted to investigate the
mechanism of injection site reactions (ISR) by examining cutaneous
cellular and proteomic changes after SQ DalcA administration in the
ex vivo human HypoSkin® biopsy platform and in vivo minipig model.
The data demonstrated that formulation buffer composition affects
DalcA MRGPRX2 (Mas-related Gprotein coupled receptor X2)-mediated
cell activation in vitro. The activation of the MRGPRX2 receptor
triggers vascular permeability, pain and itching and has been
implicated in ISRs. An optimal formulation buffer reducing MRGPRX2
activation was selected to minimize the risk of ISRs upon DalcA
administration.
“Our scientific teams have built a tremendous body of knowledge
around MarzAA and DalcA, and we are pleased to have presented some
of that at ISTH,” said Nassim Usman, Ph.D., president and
chief executive officer of Catalyst. “The data support our approach
in our ongoing trials of MarzAA in hemostasis, where we are
enrolling patients in the Crimson 1 Phase 3 registrational study as
well as in a Phase 1/2 trial.”
A copy of the presentation materials can be accessed on the
Scientific Presentations and Publications section of the
Catalyst website.
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare disorders of the complement and coagulation systems. Our
protease engineering platform has generated two late-stage clinical
programs, including MarzAA, a subcutaneously (SQ) administered
next-generation engineered coagulation Factor VIIa (FVIIa) for the
treatment of episodic bleeding in subjects with rare bleeding
disorders. Our complement pipeline includes a preclinical
C3-degrader program licensed to Biogen for dry age-related macular
degeneration, an improved complement factor I protease for SQ
replacement therapy in patients with CFI deficiency and
C4b-degraders designed to target disorders of the classical
complement pathway as well as other complement programs in
development.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include statements
about the potential uses and benefits of MarzAA and DalcA, as well
as statements about ongoing clinical trials. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially, including, but not limited to, the
risk that trials and studies may be delayed or terminated as a
result of COVID-19, competitive products and other factors, that
trials may not have satisfactory outcomes, that additional human
trials will not replicate the results from earlier trials, the risk
that costs required to develop or manufacture the Company's
products will be higher than anticipated, including as a result of
delays in trial enrollment, development and manufacturing resulting
from COVID-19 and other factors, the risk that Biogen will
terminate Catalyst's agreement, the risk that potential adverse
effects may arise from the testing or use of MarzAA, including the
generation of neutralizing antibodies, competition and other risks
described in the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on May 6, 2021, and in other filings with
the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024